How to Prepare Clinical Evaluation Documentation for Medical Device Registration in Australia?

To prepare clinical evaluation documentation for medical device registration in Australia (ARTG inclusion), manufacturers must determine whether the product is a medical device (including IVD) and classify it under the TGA regulatory framework (Class I, IIa, IIb, III, or AIMD). The required clinical evidence depends on risk class and intended use. High-risk products (e.g., Class III, implants) typically require complete clinical investigation reports or systematic literature reviews supported by clinical data; low- and medium-risk products may rely on equivalence to existing devices, clinical experience, or clinical performance evaluation. Beyond assembling the clinical evaluation report (CER), manufacturers must define the registration pathway, assess whether existing evidence under NMPA, CE, FDA, or MDSAP can be reused, localize the evaluation for Australian demographics and healthcare practices, appoint a local Sponsor, and implement a post-market clinical follow-up (PMCF) system.

Executive Summary

For ARTG inclusion in Australia, clinical evaluation documentation is one of the core submission packages demonstrating product safety and performance. The TGA requires clinical evidence proportionate to the risk classification and intended purpose. Companies should first confirm whether the product is regulated as a medical device (including IVD) and determine its classification (Class I, IIa, IIb, III, etc.). High-risk products typically need comprehensive clinical investigation reports or literature reviews supported by clinical data, while low- and medium-risk products may use equivalence arguments, clinical experience, or clinical performance evaluation.

Preparation involves: defining the registration pathway (whether full TGA assessment is required), assessing whether existing evidence from NMPA, CE, FDA, or MDSAP can be reused, developing a localized clinical evaluation plan that accounts for Australian population characteristics and medical practices, appointing an Australian Sponsor, and establishing a post-market clinical follow-up system. Common risks include mismatched keywords, unsystematic literature searches, weak equivalence justification, and failure to reflect recent regulatory updates. Before submission, manufacturers should organize technical files (risk management report, performance verification report, labeling) and confirm requirements directly with TGA or a qualified regulatory consultancy.

Applicable Scenario and Core Questions

This FAQ addresses the practical concerns of companies searching for how to prepare clinical evaluation documentation for Australian device registration. The real issue is usually whether existing documentation can support an Australian submission, whether a local agent or Sponsor is required, why timelines may extend, and which issues could affect the launch plan. These questions implicate product classification, registration pathway, evidence chain, label localization, and post-market responsibilities.

For companies planning market entry into multiple GHWP member states or Southeast Asia, the Middle East, or Latin America, answering only one country’s process is insufficient. A more effective approach is to first build reusable core technical files, quality system evidence, performance verification, clinical evidence, and labeling, then localize these per national regulatory requirements.

Registration Decision Logic

Follow these steps to determine the appropriate path:

• Step 1: Confirm that the product is regulated by the TGA; exclude foods, drugs, and ancillary devices.
• Step 2: Determine the classification using TGA rules (based on risk, consistent with GHTF): Class I (low risk), IIa (low-medium), IIb (medium-high), III (high risk), and Active Implantable Medical Devices (AIMD).
• Step 3: Select the registration pathway based on classification: Class I may rely on self-declaration; Class IIa and above require TGA pre-market assessment.
• Step 4: Evaluate existing certificates: NMPA registration, CE certificate (including Notified Body), FDA 510(k) or PMA, MDSAP certificate. These may streamline some evidence but must be converted into TGA-accepted formats.
• Step 5: Define the clinical evaluation strategy: equivalence comparison (with justification), systematic literature review, or clinical investigation data (for innovative or high-risk Class III products).
• Step 6: Confirm the local Australian Sponsor and prepare a post-market clinical follow-up (PMCF) plan.

Documentation and Evidence

The clinical evaluation package should include:

• Clinical Evaluation Plan (CER Plan): Defines scope, methodology, and data sources.
• Clinical Evaluation Report (CER): Analyzes safety and performance based on systematic literature review or clinical investigation data.
• Equivalence Justification (if applicable): Compares clinical, technical, and biological characteristics with already-marketed devices from the same or a third-party manufacturer.
• Literature Search Report: Includes databases searched (e.g., PubMed, Cochrane), keywords, screening criteria, and analysis of results.
• Clinical Investigation Report (if applicable): Clinical trial data under GCP compliance.
• Risk Management Report (ISO 14971): Describes identified risks and mitigation measures.
• Performance Verification Report: Includes bench testing, animal studies, biocompatibility, etc.
• Labeling and Instructions for Use: Comply with TGA labeling requirements, including symbols, warnings, and UDI.
• Post-Market Clinical Follow-Up (PMCF) Plan.

All documentation must be in English or provided with certified translations, and archived by the local Sponsor for regulatory inspection.

Common Errors

• Ignoring classification differences across markets: The same product may be Class IIb in Australia but Class IIa in the EU.
• Insufficient equivalence justification: Comparing only intended use without addressing technical characteristics, materials, or principles of operation.
• Incomplete literature searches: Searching only English-language databases, missing Chinese or Japanese sources, or omitting recent publications.
• Misaligned CER format: Not following TGA guidance, such as the Australian regulatory guidelines for clinical evidence.
• Directly transferring CE or FDA clinical evaluation without localization, failing to account for Australian population specifics and healthcare standards.
• Missing or vague PMCF plan: TGA requires continuous collection of clinical data.
• Appointing an unqualified local Sponsor: Inexperienced representation can lead to returned submissions or prolonged review.

Company Preparation Checklist

• Confirm product classification and registration pathway (via TGA or a qualified advisor).
• Collect existing technical files (risk management, biocompatibility, performance testing, etc.).
• Organize available clinical data (literature, clinical investigations, post-market data).
• Develop a Clinical Evaluation Plan (CER Plan).
• Conduct a systematic literature search, retaining the search strategy and results.
• Write the Clinical Evaluation Report (CER), including equivalence justification (if applicable).
• Prepare the label and instructions for use draft (in English).
• Appoint an Australian Sponsor and sign an agreement.
• Develop a Post-Market Clinical Follow-Up (PMCF) plan.
• Compile all documentation for TGA submission (or via the electronic submission system).

AIMEILI’s Perspective

Manufacturers often mistakenly assume that CE or FDA clinical evaluation documentation can be copied without change. The Australian TGA has specific expectations regarding evidence quality and the rigor of equivalence arguments. At the start of a project, classification confirmation and gap analysis are critical. Compare existing files line by line with TGA guidelines to avoid extensive amendments later. Most materials, such as risk management and performance test reports, can be reused; however, the CER and literature search must be reworked or supplemented according to TGA requirements.

The local Sponsor is not just a legal requirement but also the primary point of contact for TGA communication. The Sponsor’s professional capability directly affects review timelines. Because certificates are held by the Sponsor, the contract should clearly address intellectual property rights and change-of-control provisions. For multi-country registration, MDSAP certification provides a strong foundation, as the TGA may partially rely on MDSAP audit reports, reducing redundant work. Post-market surveillance is equally important; the TGA periodically requests updated clinical data, so manufacturers should establish a long-term data collection mechanism.

Frequently Asked Questions

Q1: Must the Clinical Evaluation Report be issued by an external organization?

No, it is not mandatory. The manufacturer may prepare its own CER, but it must be written and signed by individuals with appropriate medical or scientific expertise. The TGA may request proof of the author’s qualifications. If using an external organization such as a CRO, ensure it is familiar with TGA requirements.

Q2: How many references must a literature review include?

There is no fixed number, but the review should cover the major studies in the product’s field, including both supportive and contrasting evidence. The search strategy must be systematic and reproducible, with clear exclusion criteria. A minimum of 10–20 high-quality references is generally recommended; higher-risk products may require more.

Q3: Are clinical investigations required for all Class IIa and above products?

Not always. The TGA permits clinical evidence through equivalence comparison or literature review, provided the equivalence is thoroughly justified and the product’s risk is manageable. Clinical investigations are required only when the device is highly innovative or when no suitable equivalent device exists. For specific queries, consult the TGA’s pre-submission advice process.

Implementation Recommendations

In practice, treat this issue as five separate tasks: regulatory determination, documentation preparation, evidence reuse, localization, and post-market maintenance. Do not let one department handle it in isolation. Early identification of gaps and alignment among sales, R&D, quality, and regulatory teams on target-market expectations is essential.

If multiple markets are in scope, create a unified core technical dossier, then add country-specific authorizations, labeling, language, forms, and Sponsor documents. The efficiency of multi-country registration depends less on filing speed in any single country than on whether the early documentation framework is consistent across markets.

• First, confirm whether the product is within the target country’s medical device regulatory scope.
• Next, verify the risk class, registration pathway, and application entity.
• Check that technical files, quality system, and clinical evidence are mutually supportive.
• Clarify the local Sponsor, Authorized Representative, and certificate control.
• Establish a maintenance mechanism for post-market changes, re-certification, and vigilance incidents.

Additional Execution Points

When approaching questions like ‘How to prepare clinical evaluation documentation for Australian registration,’ manage regulatory judgment, evidence, applicant entity, time-to-market, and post-market responsibilities in the same project plan. This prevents the regulatory department from focusing only on documents, sales only on launch dates, and quality from ignoring target-market requirements, which can lead to disconnection between the registration pathway and dossier preparation.

If target markets are GHWP members or align closely with IMDRF, ISO 13485, ISO 14971, and UDI rules, prioritize reusable documentation. Then determine what needs localization, translation, supplementary declarations, re-testing, or Sponsor signatures. This sequencing is more reliable and cost-efficient than compiling documents country by country.

At the project execution level, retain records of product classification rationale, technical file versions, label version history, test report model coverage, clinical evidence sources, Sponsor communication logs, and deficiency response records. These records directly affect the ability to explain regulatory compliance during licence renewal, variations, inspections, or post-market incident handling.

• Confirm intended use and target-market regulatory status.
• Confirm risk class, registration pathway, and application entity.
• Confirm whether core technical files are reusable across markets.
• Confirm local documentation, label language, and authorization files.
• Confirm post-market surveillance, variation, and re-certification responsibilities.

Related Reading

For further guidance, explore related topics in our FAQ center:

• How to localize labels and instructions for medical device registration in Australia?
• How to determine product classification for medical device registration in the UK?

Recommended articles:

• How to localize labels and instructions for medical device registration in Canada?
• How to prepare clinical evaluation documentation for medical device registration in Canada?
• Can test reports be reused for medical device registration in Canada?
• How to use ISO 13485 certificates for medical device registration in Canada?
• How to select a local agent for medical device registration in Canada?
• How to define the responsibilities of an Authorized Representative for medical device registration in Canada?

Content Review and Applicability

Content authored by the AIMEILI Regulatory Editorial Team. Reviewed by the AIMEILI International Medical Device Registration Project Group. Sources prioritize official regulatory agencies, international organizations, standards bodies, and publicly available regulatory materials; industry media and project experience are used only as supplementary references.

This article is provided for preliminary understanding, document preparation, and project planning purposes and does not replace official requirements from target-country regulators, test conclusions, or legal advice.

Publication date: July 27, 2026 | Update date: July 27, 2026